The Role of Trimetazidine After Acute Myocardial Infarction

Author(s): Maciej Banach, Jacek Rysz, Aleksander Goch, Dimitri P. Mikhailidis, Giuseppe M.C. Rosano.

Journal Name: Current Vascular Pharmacology

Volume 6 , Issue 4 , 2008

Become EABM
Become Reviewer

Abstract:

“Metabolic treatment” involves the use of drugs to improve cardiomyocyte function. Trimetazidine is the most investigated drugs in this group. The ESC 2006 guidelines on the management of patients with stable angina mention the efficacy of metabolic treatment in improving physical efficiency and decreasing the recurrence of pain. The available data suggest that combined therapy of trimetazidine and haemodynamic drugs is an effective antianginal treatment that reduces the risk of pain recurrence (in as many as 64% of patients). The most recent studies also suggest that trimetazidine might be effective in patients with acute coronary syndromes, ischemic cardiomyopathy and heart failure. However, while trimetazidine has shown beneficial effects on surrogate endpoints in several small trials its effect on cardiovascular events is uncertain. Further large randomized studies are needed before its effects on cardiovascular events can be evaluated.

Keywords: Acute coronary syndromes, metabolic treatment, trimetazidine

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 6
ISSUE: 4
Year: 2008
Page: [282 - 291]
Pages: 10
DOI: 10.2174/157016108785909788
Price: $58

Article Metrics

PDF: 4